title: Lipid effects and cardiovascular disease risk associated with glucose-lowering medications.
abstract: Diabetes is a global epidemic, associated with a high burden of complications and 4.6 million deaths annually worldwide. As a result of decreasing levels of physical activity and increasing rates of obesity, diabetes is shifting from a disease affecting the elderly to one that affects younger patients or even children. Thus, aggressive treatment and optimal control of risk factors is the key to improve outcomes in those patients. Accumulating evidence of the cardiovascular and lipid effects of glucose-lowering medications suggest that treatment efficacy in diabetes can be further improved. This review provides an overview of the lipid effects and cardiovascular disease risk of current anti-diabetic medications and highlights opportunities and challenges in clinical practice.
authors.affiliation: Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec, H1T 1C8, Canada, barbarastaehli@hotmail.com.
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Stähli
authors.forename: Catherine
authors.initials: C
authors.lastname: Gebhard
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000139:chemically induced* / Q000517:prevention & control; D004334:Drug Administration Schedule; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000097:blood / Q000150:complications*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D008055:Lipids